-
公开(公告)号：US07247454B2
公开(公告)日：2007-07-24
申请号：US10324182
申请日：2002-12-20
Applicant: Marc D. Better , Patrick D. Gavit
Inventor： Marc D. Better , Patrick D. Gavit
CPC classification number: C12N15/62 , C07K14/4742 , C07K14/51 , C07K2319/00 , C07K2319/35 , C12N15/70
Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells.
Abstract translation: 本发明提供了用于从细菌细胞生产重组肽的改进方法。
-
公开(公告)号：US06500648B1
公开(公告)日：2002-12-31
申请号：US09760397
申请日：2001-01-12
Applicant: Marc D. Better , Patrick D. Gavit
Inventor： Marc D. Better , Patrick D. Gavit
IPC: C12P2104
CPC classification number: C12N15/62 , C07K14/4742 , C07K14/51 , C07K2319/00 , C07K2319/35 , C12N15/70
Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells.
Abstract translation: 本发明提供了用于从细菌细胞生产重组肽的改进方法。
-
公开(公告)号：US07749731B2
公开(公告)日：2010-07-06
申请号：US11762486
申请日：2007-06-13
Applicant: Marc D. Better , Patrick D. Gavit
Inventor： Marc D. Better , Patrick D. Gavit
CPC classification number: C12N15/62 , C07K14/4742 , C07K14/51 , C07K2319/00 , C07K2319/35 , C12N15/70
Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells.
Abstract translation: 本发明提供了用于从细菌细胞生产重组肽的改进方法。
-
公开(公告)号：US20090246831A1
公开(公告)日：2009-10-01
申请号：US11762486
申请日：2007-06-13
Applicant: Marc D. Better , Patrick D. Gavit
Inventor： Marc D. Better , Patrick D. Gavit
IPC: C12P21/00
CPC classification number: C12N15/62 , C07K14/4742 , C07K14/51 , C07K2319/00 , C07K2319/35 , C12N15/70
Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells.
Abstract translation: 本发明提供了用于从细菌细胞生产重组肽的改进方法。
-
公开(公告)号：US06242219B1
公开(公告)日：2001-06-05
申请号：US09271970
申请日：1999-03-18
Applicant: Marc D. Better , Patrick D. Gavit
Inventor： Marc D. Better , Patrick D. Gavit
IPC: C12P2104
CPC classification number: C12N15/62 , C07K14/4742 , C07K14/51 , C07K2319/00 , C07K2319/35 , C12N15/70
Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells in which acid Lysis of the peptide occurs in cell culture media.
Abstract translation: 本发明提供了从细菌细胞中产生重组肽的改进方法，其中肽在细胞培养基中发生酸裂解。
-
Patent Agency Ranking
公开(公告)号：US6146850A
公开(公告)日：2000-11-14
申请号：US136389
申请日：1998-08-18
Applicant: Marc D. Better , Stephen F. Carroll
Inventor： Marc D. Better , Stephen F. Carroll
IPC: A61K38/00 , A61K47/48 , C07K14/415 , C07K16/00 , C07K16/16 , C07K16/28 , C12N1/21 , C12N15/29 , C12P21/02
CPC classification number: A61K47/48561 , A61K47/48469 , C07K14/415 , C07K16/00 , C07K16/16 , C07K16/28 , C07K16/2896 , A61K38/00 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2319/00
Abstract: The present invention provides purified proteins that contain gelonin amino acid sequences that have enzymatic activity.
Abstract translation: 本发明提供含有具有酶活性的gelonin氨基酸序列的纯化蛋白质。
-
公开(公告)号：US5851802A
公开(公告)日：1998-12-22
申请号：US621803
申请日：1996-03-22
Applicant: Marc D. Better
Inventor： Marc D. Better
IPC: C12N15/09 , A61K38/00 , C07K2/00 , C07K14/47 , C12N1/21 , C12N15/12 , C12N15/62 , C12P21/02 , C12P21/06 , C12R1/19 , C12M15/62
CPC classification number: C12N15/62 , C07K14/4742 , A61K38/00 , C07K2319/00 , C07K2319/02
Abstract: The present invention relates to methods and materials for the recombinant microbial production of fusion proteins and peptides derived from or based on Domain I (amino acids 17-45), Domain II (amino acids 65-99) and Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI).
-
公开(公告)号：US07153932B2
公开(公告)日：2006-12-26
申请号：US10717243
申请日：2003-11-18
Applicant: Marc D. Better , Stephen F. Carroll , Gary M. Studnicka
Inventor： Marc D. Better , Stephen F. Carroll , Gary M. Studnicka
CPC classification number: C07K14/415 , A61K38/00 , A61K47/6825 , A61K47/6849 , A61K2121/00 , C07K16/00 , C07K16/16 , C07K16/28 , C07K16/2896 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2319/00 , Y10S530/866
Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
-
公开(公告)号：US5837491A
公开(公告)日：1998-11-17
申请号：US646360
申请日：1996-05-13
Applicant: Marc D. Better , Stephen F. Carroll , Gary M. Studnicka
Inventor： Marc D. Better , Stephen F. Carroll , Gary M. Studnicka
IPC: A61K38/00 , A61K47/48 , C07K14/415 , C07K16/00 , C07K16/16 , C07K16/28 , C12N1/21 , C12N15/29 , C12P21/02
CPC classification number: A61K47/48469 , A61K47/48561 , C07K14/415 , C07K16/00 , C07K16/16 , C07K16/28 , C07K16/2896 , A61K38/00 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2319/00
Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
Abstract translation: PCT No.PCT / US94 / 05348 Sec。 371日期：1996年5月13日 102（e）日期1996年5月13日PCT提交1994年5月12日PCT公布。 第WO94 / 26910号公报 日期1994年11月24日本发明提供了编码I型核糖体失活蛋白（RIP）的纯化和分离的多核苷酸以及具有可用于二硫键与靶向分子的半胱氨酸的RIP的类似物。 还提供了包含用载体转化的多核苷酸和宿主细胞的载体。 RIP和RIP类似物特别适合用作本发明的细胞毒性治疗剂的组分，其包括基因融合产物和免疫缀合物。 根据本发明的细胞毒性治疗剂或免疫毒素可以用于选择性地消除RIP组分靶向的任何细胞类型，其中所述试剂的第二组分的特异结合能力适合于治疗消除 特定的细胞类型是目标，例如自身免疫疾病，癌症和移植物抗宿主病。
-
公开(公告)号：US5756699A
公开(公告)日：1998-05-26
申请号：US477484
申请日：1995-06-07
Applicant: Marc D. Better , Stephen F. Carroll , Gary M. Studnicka
Inventor： Marc D. Better , Stephen F. Carroll , Gary M. Studnicka
IPC: A61K38/00 , A61K47/48 , A61P35/00 , A61P37/06 , C07K14/415 , C07K16/00 , C07K16/16 , C07K16/28 , C12N1/21 , C12N15/29 , C07H21/04 , C12P21/04
CPC classification number: A61K47/48469 , A61K47/48561 , C07K14/415 , C07K16/00 , C07K16/16 , C07K16/28 , C07K16/2896 , A61K2121/00 , A61K38/00 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2319/00 , Y10S530/866
Abstract: The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.027 seconds)
